Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Liabilities (2016 - 2026)

Intellia Therapeutics has reported Total Liabilities over the past 12 years, most recently at $137.8 million for Q1 2026.

  • Quarterly Total Liabilities fell 33.17% to $137.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $137.8 million through Mar 2026, down 33.17% year-over-year, with the annual reading at $170.7 million for FY2025, 46.49% down from the prior year.
  • Total Liabilities was $137.8 million for Q1 2026 at Intellia Therapeutics, down from $170.7 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $319.1 million in Q4 2024 and troughed at $137.8 million in Q1 2026.
  • The 5-year median for Total Liabilities is $220.5 million (2024), against an average of $222.0 million.
  • Year-over-year, Total Liabilities surged 45.62% in 2022 and then tumbled 46.49% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $284.5 million in 2022, then dropped by 11.85% to $250.8 million in 2023, then rose by 27.21% to $319.1 million in 2024, then tumbled by 46.49% to $170.7 million in 2025, then decreased by 19.27% to $137.8 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Total Liabilities are $137.8 million (Q1 2026), $170.7 million (Q4 2025), and $176.9 million (Q3 2025).